AnaptysBio Inc. (ANAB) Quality Score
Business quality remains strong (avg 100/100), but valuation is pulling the composite down (avg 20/100).
Broad-market heuristics · Not a buy/sell signal
Valuation
Growth
Negative earnings, no valuation support
Above 30x, cash flow yield is thin
Above 10% CAGR, strong compounder
Recently turned FCF-positive, capex cycle finishing, CAGR not yet meaningful
Business Quality & Capital Allocation
Shrinking >2%, active buybacks
Expanded 3+pp, strong improvement
Net cash position, no leverage concern
Above 20%, exceptional capital efficiency
AnaptysBio (ANAB) quality: score, margins and returns
AnaptysBio (ANAB) scores 75/100 on Intrinsiqq's quality score (a solid business), a weighted blend of 6 metrics each scored 0 to 100, on 17.6% operating margins and 204.0% ROIC. Every metric is computed from SEC filings; this is analysis, not investment advice.
Frequently asked
Is AnaptysBio (ANAB) a high-quality business?+
AnaptysBio scores 75 out of 100 on Intrinsiqq's quality score, a weighted blend of 6 metrics each scored 0 to 100, which rates it a solid business on these measures. Recent figures include a 17.6% operating margin and a 204.0% return on invested capital. Quality and price are separate questions: even a great business can be a poor investment if you overpay, so read this score alongside the valuation. The metric-by-metric breakdown is on this scorecard.
What does AnaptysBio's quality score measure?+
Intrinsiqq's quality score weighs revenue and free-cash-flow growth, operating margins, return on invested capital, change in share count, and balance-sheet strength, each computed from ANAB's SEC filings rather than opinion or sentiment. A higher score means a more durable, capital-efficient business; it is not a buy or sell signal. Open each metric on this page to see exactly where AnaptysBio scores well and where it falls behind.
What is AnaptysBio's return on invested capital (ROIC)?+
AnaptysBio earns about 204.0% on its invested capital, which is exceptional. ROIC measures how much profit a company generates per dollar put to work; sustained ROIC above its cost of capital is one of the clearest signs of a real competitive moat. Compare it to ANAB's margins and growth on this scorecard to judge durability.
How profitable is AnaptysBio?+
AnaptysBio runs an operating margin of about 17.6% and a net margin of about -11.5%. Revenue has grown at roughly 25.6% a year recently. High, stable margins usually point to pricing power and operating discipline. Margins are most telling next to growth and returns on capital, all of which feed this quality score. This is analysis from SEC filings, not investment advice.
SourceQuality score computed from the 10-Q filed 12 May 2026, covering the period ending 31 Mar 2026, as reported to the SEC. Data last refreshed 13 May 2026. How this is calculated.
Fiscal year ends Dec. Sector medians are approximate S&P 500 benchmarks and update periodically. Checks use broad-market heuristics, so sector norms may differ, and the valuation checks are more cyclical than the quality checks.
Related stocks: Pharmaceutical Preparations
Data sourced from SEC EDGAR filings and third-party price providers. Scores, valuations, and metrics are algorithmic estimates. This is not investment advice. See our Terms and Methodology.